Celltrion

Dear Valued Shareholders,

On September 20 (local time), Celltrion entered into an agreement with global pharmaceutical company Eli Lilly to acquire its U.S. manufacturing facility. We have completed all required regulatory procedures related to the acquisition.

We would like to take this opportunity to promptly share with our shareholders the details and progress of this important development.

Following approval from Ireland’s Competition and Consumer Protection Commission (CCPC) last month, Celltrion has recently completed the “business combination” review process conducted by the Premerger Notification Office (PNO) of the U.S. Federal Trade Commission (FTC).

The “business combination” review is a process to assess whether a merger or asset acquisition could potentially hinder market competition. Celltrion is to undergo regulatory reviews under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in the United States and by the relevant authorities in Ireland due to exceeding certain local revenue thresholds.

Upon deal closing, Celltrion plans to accelerate post-merger integration (PMI) by dispatching key personnel across various business areas to ensure a seamless transition with no disruption to operations. We will also provide tailored support to help existing local employees adapt quickly to organizational changes, taking into account regional characteristics.

Through this acquisition, Celltrion secures multiple strategic advantages: elimination of tariff-related risks, mitigation of geopolitical uncertainties through manufacturing site diversification, and expansion of contract manufacturing (CMO) opportunities within the United States.

In particular, the CMO business will be actively expanded around the Branchburg facility, leveraging the growing demand for pharmaceutical production in the U.S. Given the growing demand for CMO services in the U.S, Celltrion plans to utilize its extensive track record in biopharmaceutical development, manufacturing, and new drug CMO projects to attract new clients. Under the previously agreed CMO contract with Eli Lilly, revenue generation will begin immediately upon acquisition, allowing for early recovery of investment.

Going forward, Celltrion will continue to pursue top-tier business performance while implementing shareholder-friendly policies to enhance shareholder value. We also remain committed to maintaining transparent and consistent communication regarding the company’s business plans and outlook.

We sincerely thank all our shareholders for your continued trust and support for Celltrion.